Nektar Therapeutics Analysts Call with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting Transcript
Ladies and gentlemen, thank you for standing by and welcome to the Nektar Therapeutics SITC Analyst Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Ms. Jennifer Ruddock, Head of Corporate Affairs. Ma'am, you may begin.
Thank you, Krystal. Good afternoon, everyone, and thank you for joining us on today's analyst call to review data presented for Nektar's I-O pipeline at the 2020 SITC meeting.
Before we start, I'll remind you that this presentation includes forward-looking statements regarding Nektar's drug candidates bempegaldesleukin, NKTR-262 and NKTR-255 and other potential drug candidates; clinical trial results; the timing of the start of and plan for ongoing or planned clinical trials with partners; the therapeutic potential of our drug candidates; the timing and outcome of regulatory decisions; and future availability of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
